Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma characterized by MYC dysregulation.
|
28619753 |
2017 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
MYC protein staining of >50% of lesional cells was identified in 60% of Burkitt lymphomas, 50% of B lymphoblastic lymphomas, 33% of T lymphoblastic lymphomas, 31% of rhabdomyosarcomas, 33% of Ewing sarcomas, and 25% of soft tissue sarcomas, not otherwise specified.
|
28521631 |
2017 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
MYC-R lymphomas show poor outcomes even when treated with intensive immunochemotherapy for BL.
|
28648593 |
2017 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
High-resolution structural and functional genomic analysis of adult Burkitt lymphoma (BL) and high-grade B-cell lymphoma with BL gene signature (adult-molecularly defined BL [mBL]) revealed the MYC-ARF-p53 axis as the primary deregulated pathway.
|
28801451 |
2017 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Oligonucleotide sets that probe breakpoints of <i>IGH-BCL2</i> (immunoglobulin heavy-apoptosis regulator) in follicular lymphoma (FL), <i>MYC-IGH</i> (MYC proto-oncogene, bHLH transcription factor-immunoglobulin heavy) in Burkitt lymphoma (BL) and <i>BCR-ABL1</i> (RhoGEF and GTPase activating protein-ABL proto-oncogene 1, non-receptor tyrosine kinase) in chronic myelogenous leukemia (CML) were designed.
|
28515100 |
2017 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Here we study the effects of BCR ablation on MYC-driven mouse B-cell lymphomas and compare them with observations in human Burkitt lymphoma.
|
28562582 |
2017 |
Burkitt Lymphoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Hence, shRNA-mediated knock-down of endogenous MYC in human T-ALL and Burkitt's lymphoma cell lines downregulated DNMT3B expression.
|
29100357 |
2017 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The c-MYC oncogene is overactivated during Burkitt's lymphoma pathogenesis.
|
28603988 |
2017 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
All BLs carried MYC translocation (P<0.001), whereas LMO2 was only positive in 6/42 (14%) LBCL with MYC translocation (P<0.001).
|
28288039 |
2017 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The 11q-gain/loss is not specific for BLL, 11q, but occurs recurrently in MYC-positive BL and MYC-positive HGBL.
|
29272887 |
2017 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
MYC dysregulation needs other cooperating events for BL development.
|
26887776 |
2016 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Chromosome 8q24/MYC rearrangement is associated with Burkitt lymphoma and some aggressive B-cell lymphomas, but is rare in chronic lymphocytic leukemia.
|
26916070 |
2016 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
All cases showed morphologic and immunophenotypic features of Burkitt lymphoma with MYC rearrangement in all 5 cases tested.
|
27257042 |
2016 |
Burkitt Lymphoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
This case report documents a 5-year-old female who presented with B-cell lymphoma with lymphoblastic morphology, terminal deoxynucleotidyl transferase expression, MYC rearrangement, and features overlapping with BL.
|
26785246 |
2016 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
MYC heteroclonality was not observed in Burkitt lymphoma and all cases had positive MYC expression.
|
27125356 |
2016 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Burkitt lymphoma (BL) is an aggressive B cell lymphoma characterized by the reciprocal translocation of the c-Myc gene with immunoglobulin genes.
|
27044389 |
2016 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
MYC translocations occurred as single hit (only MYC rearranged, 63%) or multiple hit lymphoma (37%) and presented as acute leukemia (AL) (14%), Burkitt lymphoma (30%), chronic lymphocytic leukemia (CLL) (21%) or other mature B-cell neoplasms (35%).
|
27810071 |
2016 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In vivo studies using a mouse model of Burkitt's Lymphoma provide pre-clinical evidence that these antibiotics can successfully block progression of MYC-dependent tumors.
|
27590350 |
2016 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The correlation of EZH2 expression with aggressive behavior and proliferation rate in B-cell neoplasms suggests that this molecule may function as an oncogenic protein in these neoplasms, with possible regulation by different signaling cascades in different types of aggressive B-cell lymphomas: p-ERK-related signaling in diffuse large B-cell lymphoma, and MYC-related signaling in Burkitt lymphoma and double hit lymphoma.
|
27282353 |
2016 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
However, we know little about the incidence of MYC/BCL2 double-hit (DH) in BL.
|
26182827 |
2015 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We studied the microRNA profile of MYC translocation-positive and MYC translocation-negative Burkitt lymphoma cases in order to uncover possible differences at the molecular level.
|
26453442 |
2015 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The Burkitt lymphomas had a MYC rearrangement.
|
25403088 |
2015 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Here we performed whole-genome bisulfite, genome and transcriptome sequencing in 13 IG-MYC translocation-positive Burkitt lymphoma, nine BCL2 translocation-positive follicular lymphoma and four normal germinal center B cell samples.
|
26437030 |
2015 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The genetic hallmark of Burkitt lymphoma is the translocation t(8;14)(q24;q32), or one of its light chain variants, resulting in IG-MYC juxtaposition.
|
26173642 |
2015 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Yet missense changes to MYC are found in ~50% of Burkitt's lymphomas, aggregate within an amino-terminal degron important for proteasomal destruction of MYC, and where examined profoundly enhance the tumorigenic properties of MYC in vitro and in vivo.
|
24998853 |
2015 |